Intersect ENT, Inc. (XENT)
(Delayed Data from NSDQ)
$33.65 USD
+1.22 (3.76%)
Updated May 3, 2019 04:00 PM ET
After-Market: $33.66 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$33.65 USD
+1.22 (3.76%)
Updated May 3, 2019 04:00 PM ET
After-Market: $33.66 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
What's in Store for Intersect ENT's (XENT) Q1 Earnings?
by Zacks Equity Research
PROPEL and SINUVA are expected to have contributed to Intersect ENT's (XENT) first-quarter revenues.
Intersect ENT (XENT) Down 5.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 Beaten-Down MedTech Stocks to Scoop Up Amid the Pandemic
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks - IVC, MCK, HRC - which are expected to provide long-term gains in 2021.
Intersect ENT (XENT) Hit by Low ENT Office Visits Amid COVID-19
by Zacks Equity Research
Intersect ENT (XENT) is worried about the first-quarter performance as well on the significant surge in COVID-19 case rates.
New Strong Sell Stocks for March 17th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Intersect ENT (XENT) Q4 Loss Wider Than Expected, Revenues Top
by Zacks Equity Research
Intersect ENT's (XENT) sequentially rebound is strong on continued recovery in PROPEL, growth in SINUVA and initial sales of the company???s newly acquired Fiagon products.
Intersect ENT (XENT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intersect ENT (XENT) delivered earnings and revenue surprises of -74.19% and 1.14%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Intersect ENT (XENT)
by Zacks Equity Research
Intersect ENT (XENT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Intersect ENT (XENT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Intersect ENT (XENT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cooper Companies (COO) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal first-quarter results are likely to reflect strength at MiSight 1-day contact lens.
What's in Store for Patterson Companies' (PDCO) Q3 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect improvement at Dental segment.
Veeva Systems (VEEV) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal fourth-quarter results are likely to reflect solid show by its segments and robust product portfolio.
Intersect ENT's (XENT) SDS With PROPEL Mini Now in U.S.
by Zacks Equity Research
Intersect ENT's (XENT) SDS, packaged with its PROPEL Mini Sinus Implant, is expected to boost the company's business following its U.S. availability.
Intersect ENT's (XENT) Q4 Preliminary Revenues Disappointing
by Zacks Equity Research
Per the preliminary announcement, Intersect ENT (XENT) projects Q4 revenues to decline from the year-ago quarter's reported figure.
Intersect ENT (XENT) Banks on SINUVA Sales Amid COVID-19 Woes
by Zacks Equity Research
Intersect ENT's (XENT) potential in chronic sinusitis market and progress in SINUVA and PROPEL product lines are encouraging.
Intersect ENT (XENT) Up 17.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intersect ENT (XENT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Intersect ENT's (XENT) PROPEL implants gain momentum and recapture procedure volume in Q3 following the drop in elective sinus procedures.
Intersect ENT (XENT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intersect ENT (XENT) delivered earnings and revenue surprises of 22.73% and 0.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Intersect ENT (XENT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Intersect ENT (XENT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intersect ENT (XENT) Posts Preliminary Q3 Data, Dull Q4 View
by Zacks Equity Research
Intersect ENT (XENT) expects the strength in its product lines to have substantially boosted revenues in the third quarter.
Intersect ENT, AllianceRx Execute Pharmacy-Services Agreement
by Zacks Equity Research
Intersect ENT (XENT) partners with AllianceRx to expand the access to SINUVA Sinus Implant.
Why Is Intersect ENT (XENT) Down 1.2% Since Last Earnings Report?
by Zacks Equity Research
Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intersect ENT (XENT) Q2 Loss Widens, Revenues Beat Estimates
by Zacks Equity Research
Although Intersect ENT's (XENT) Q2 sales are down year over year, it's stronger than expected, led by the return of sinus surgery procedures using PROPEL.
Intersect ENT (XENT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intersect ENT (XENT) delivered earnings and revenue surprises of -30.00% and 24.81%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Intersect ENT (XENT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Intersect ENT (XENT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.